PT - JOURNAL ARTICLE AU - Dowell, Alexander C. AU - Butler, Megan S. AU - Jinks, Elizabeth AU - Tut, Gokhan AU - Lancaster, Tara AU - Sylla, Panagiota AU - Begum, Jusnara AU - Bruton, Rachel AU - Pearce, Hayden AU - Verma, Kriti AU - Logan, Nicola AU - Tyson, Grace AU - Spalkova, Eliska AU - Margielewska-Davies, Sandra AU - Taylor, Graham S. AU - Syrimi, Eleni AU - Baawuah, Frances AU - Beckmann, Joanne AU - Okike, Ifeanyichukwu AU - Ahmad, Shazaad AU - Garstang, Joanna AU - Brent, Andrew J AU - Brent, Bernadette AU - Ireland, Georgina AU - Aiano, Felicity AU - Amin-Chowdhury, Zahin AU - Jones, Samuel AU - Borrow, Ray AU - Linley, Ezra AU - Wright, John AU - Azad, Rafaq AU - Waiblinger, Dagmar AU - Davis, Chris AU - Thomson, Emma AU - Palmarini, Massimo AU - Willett, Brian J. AU - Barclay, Wendy S. AU - Poh, John AU - Saliba, Vanessa AU - Amirthalingam, Gayatri AU - Brown, Kevin E AU - Ramsay, Mary E AU - Zuo, Jianmin AU - Moss, Paul AU - Ladhani, Shamez TI - Children develop robust and sustained cross-reactive spike-specific immune responses following SARS-CoV-2 infection AID - 10.1101/2021.04.12.21255275 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.12.21255275 4099 - http://medrxiv.org/content/early/2021/09/28/2021.04.12.21255275.short 4100 - http://medrxiv.org/content/early/2021/09/28/2021.04.12.21255275.full AB - SARS-CoV-2 infection is generally mild or asymptomatic in children but the biological basis for this is unclear. We studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults. Antibody responses against spike and receptor binding domain (RBD) were high in children and seroconversion boosted antibody responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Seroneutralisation assays against alpha, beta and delta SARS-CoV-2 variants demonstrated comparable neutralising activity between children and adults. T cell responses against spike were >2-fold higher in children compared to adults and displayed a TH1 cytokine profile. SARS-CoV-2 spike-specific T cells were also detected in many seronegative children, revealing pre-existing responses that were cross-reactive with seasonal Alpha and Beta-coronaviruses. Importantly, all children retained high antibody titres and cellular responses at 6 months after infection whilst relative antibody waning was seen in adults. Spike-specific responses in children also remained broadly stable beyond 12 months. Children thus distinctly generate robust, cross-reactive and sustained immune responses after SARS-CoV-2 infection with focussed specificity against spike protein. These observations demonstrate novel features of SARS-CoV-2-specific immune responses in children and may provide insight into their relative clinical protection. Furthermore, this information will help to guide the introduction of vaccination regimens in the paediatric population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC). We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI. The study was also funded in part by the MRC (MC UU 1201412).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PHE Research Ethics Governance Group (reference NR0209; May 16, 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available following reasonable requests.